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Kathryn B. Garber1,*A New Aspect of Loeys-Dietz Syndrome: Allergies
As with Marfan syndrome, Loeys-Dietz syndrome (LDS)
was originally viewed solely through the lens of a connec-
tive-tissue disorder because of the classic clinical presenta-
tion, which includes joint laxity. It came as a surprise when
mutations in genes encoding TGF-b receptors 1 and 2 were
found to be responsible for LDS. Hal Dietz’s research group
has been dissecting the role of TGF-b dysregulation in the
Marfan syndrome and LDS phenotypes, particularly in
terms of the development of aortic aneurysm. Looking
beyond the cardiovascular phenotype, they also got to
thinking about the role of TGF-b in the immune system
and whether there could be immune-related phenotypes
associated with LDS. In a sample of 58 patients, they found
a higher prevalence of several allergy-related phenotypes,
including food allergy, asthma, eosinophilic gastrointes-
tinal disease, and eczema, than in the general population.
Underlying these diagnoses, LDS patients have elevated
immunoglobulin E levels, eosinophil counts, and T helper
2 cytokines in their plasma. Beyond the implications
for LDS, the fact that mutations in a single gene can be
directly tied to allergic disease might increase our under-
standing of the development of the more common forms
of allergy.
Frischmeyer-Guerrerio et al. (2013). Sci. Transl. Med. 5,
195ra94.
A New Aspect of Rett Syndrome: Altered Cholesterol
Metabolism
Although Rett syndrome is a progressive phenotype that
ends in death, restoring expression of the missing gene,
Mecp2, in mutant mice—even after they develop features
of the disease—improves some of their neurological
deficits and prolongs survival. This got Buchovecky et al.
to thinking that treatment of Rett syndrome might be
possible and that they could uncover relevant pathways
in Rett syndrome pathogenesis through a suppressor
screen in mice. Their screen of ENU-mutagenized Mecp2-
null mice was successful, and one of the suppressor lines
they isolated had a nonsense mutation in the gene encod-
ing squalene epoxidase, a rate-limiting enzyme in choles-
terol biosynthesis. In fact, mice lacking Mecp2 had
abnormal cholesterol metabolism, a previously unrecog-
nized aspect of their phenotype. What are humans with
high cholesterol prescribed? Often, a statin. Although it
is not a panacea for Mecp2 mutant mice, treatment with1Department of Human Genetics, Emory University School of Medicine, Atlan
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The Americanstatins alleviates their motor symptoms and increases their
longevity, giving hope that this already widely used drug
could be a potential intervention for children with Rett
syndrome.
Buchovecky et al. (2013). Nat. Genet. Published online July
28, 2013. 10.1038/ng.2714.
Incidental Findings, Autonomy, and Paternalism
A great deal of discussion has been generated by the recent
recommendations of the American College of Medical
Genetics (ACMG) on the reporting of incidental findings
that result from whole-genome or whole-exome sequenc-
ing. The ACMG position argues that clinical testing labora-
tories should report certain medically actionable findings
that are unrelated to the original indication for testing,
regardless of the age of the patient. Although some argue
that this denies patient autonomy, others argue that there
is a duty to warn patients when harm can be avoided.
Three points of view on these issues were published
recently in JAMA, and they provide a nice comparison of
ideas and a discussion of the relevant ethical principles
that can be used to inform decision-making around
incidental findings. Should they be treated as different
from other incidental findings in medicine? Some say
yes, others say no.
Green et al. (2013). JAMA 310, 365–366.
Ross et al. (2013). JAMA 310, 367–368.
Klitzman et al. (2013). JAMA 310, 369–370.
Treating Osteogenesis Imperfecta with a Pill
Although our understanding of their utility and side-
effects is incomplete, bisphosphonates are used to suppress
bone resorption in some patients with osteogenesis
imperfecta (OI). Generally, these are given intravenously
at regular intervals, which can be a burden to patients,
families, and clinics. Bishop et al. recently performed a
randomized double-blind trial to assess whether the
bisphosphonate risedronate could instead be given to
affected children in pill form. In this international trial
of patients—generally with mild disease—those given
risedronate had significantly larger increases in lumbar
spine areal bone mineral density and fewer nonvertebral
fractures than did those given a placebo. Risedronate also
increased the time to the first fracture during the trial
period. On the other hand, no difference in risk of
vertebral fractures was observed in this study. Whetherta, GA 30322, USA
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children with OI should be treated with intravenous or
oral bisphosphonates, or any at all, is still a matter of
debate, but this trial at least leaves an oral option on the
table.
Bishop et al. (2013). Lancet. Published online August 5,
2013. 10.1016/S0140-6736(13)61091-0.
Translocations in Real Time
What we know about translocations we have learned after
they happen. A patient is referred for genetic testing, a
translocation is detected, and then groups of these patients
can be studied with the hope that the mechanism of
translocation can be better understood. With a newmicro-
scopy technique developed by Roukos et al., translocations
can be observed as they happen. The system is artificial in410 The American Journal of Human Genetics 93, 409–410, Septembthat it involves the integration into a cell line of specific
restriction endonuclease sites for the induction of
double-strand breaks. These are flanked by Lac operator
and Tet operator sites, which can be stained with GFP-
Lac repressor and mCherry-Tet repressor, respectively. If
the labeled sequences colocalize for extended periods of
time, a translocation has occurred, and it can be confirmed
by PCR. In their initial report, Roukos et al. found that
translocations occur within hours after a double-strand
break, that they usually occur between genomic regions
that are already located near each other, and that the
DNA-damage-response pathway acts downstream of the
pairing of double-strand breaks to regulate the transloca-
tion process.
Roukos et al. (2013). Science 341, 660–664.This Month in Our Sister JournalsDetecting Local Adaptations
To find loci that are important for adaptation to local envi-
ronments, one can compare allele frequencies between the
local populations. At face value, this is a simple strategy,
but it gets more complicated when one realizes the need
to account for shared population history and the fact
that sampling gives one an incomplete picture of popula-
tion allele frequencies. To address this problem, Gu¨ntherand Coop developed an approach that uses a Bayesian
model and accounts for these potential confounders. The
model is extended for use with next-generation sequence
data from population pools and is tested with data from
the Human Genome Diversity Panel, as well as pooled
data from Atlantic herring.
Gu¨nther and Coop. (2013). Genetics. Published online July 5,
2013. 10/1534/genetics.113.152462.er 5, 2013
